FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Renata Expandable Growth Stent OKd for Infants

[ Price : $8.95]

FDA approves a Renata Medical PMA for its Minima Growth Stent thats intended for treating congenital heart disease in infants and ...

Exelas Fentanyl Not Withdraw Over Safety/Efficacy

[ Price : $8.95]

Federal Register notice: FDA determines that Exela Pharma Sciences fentanyl citrate injections, equivalent to 2.5mg/50mL and 5mg/1...

Mirum Pharma Wins Priority Review Voucher

[ Price : $8.95]

Federal Register notice: FDA announces that it issued Mirum Pharmaceuticals a priority review voucher for its approved rare pediat...

Leqvio Successfully Lowers LDL-C: Study

[ Price : $8.95]

Novartis says its Leqvio successfully lowered LDL cholesterol as a monotherapy in the Phase 3 V-MONO trial.

FDA Warns Companies on Unapproved CPAP Cleaners

[ Price : $8.95]

FDA warns three companies illegally marketing CPAP cleaning/sanitizing devices in the U.S.

Soleno Therapeutics NDA for Prader-Willi Drug

[ Price : $8.95]

FDA accepts for priority review a Soleno Therapeutics NDA for DCCR (diazoxide choline) for treating Prader-Willi syndrome (PWS) in...

SpringWorks Therapeutics NDA Accepted by FDA

[ Price : $8.95]

FDA accepts for priority review a SpringWorks Therapeutics NDA for mirdametinib, an investigational MEK inhibitor for treating ped...

Liveyon Founder Pleads Guilty

[ Price : $8.95]

Liveyon founder and CEO John Kosolcharoen pleads guilty to a felony charge of introducing an unapproved new stem cell product into...

Malfunction Reporting Program Guidance

[ Price : $8.95]

FDA publishes a guidance describing and clarifying several aspects of the Voluntary Malfunction Summary Reporting program.

Require More Breakthrough Postmarket Studies: Research

[ Price : $8.95]

Researchers call on FDA to require postmarketing studies for breakthrough therapy-designated drugs studied with surrogate endpoint...